{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T07:16:14Z","timestamp":1783149374431,"version":"3.54.6"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005683","name":"Kyoto University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005683","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24H02659"],"award-info":[{"award-number":["24H02659"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jiac.2026.102986","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:09:17Z","timestamp":1778108957000},"page":"102986","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Valganciclovir therapeutic drug monitoring-guided dosing for cytomegalovirus prophylaxis in lung transplant patients"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0803-8823","authenticated-orcid":false,"given":"Yoshiki","family":"Katada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1963-2510","authenticated-orcid":false,"given":"Keisuke","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1285-122X","authenticated-orcid":false,"given":"Shunsaku","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3003-3238","authenticated-orcid":false,"given":"Yurie","family":"Katsube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machiko","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moto","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8344-2469","authenticated-orcid":false,"given":"Daiki","family":"Hira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9474-5107","authenticated-orcid":false,"given":"Masahiro","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0789-2350","authenticated-orcid":false,"given":"Satona","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4559-9753","authenticated-orcid":false,"given":"Tomohiro","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2026.102986_bib1","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1097\/TP.0000000000000549","article-title":"Incidence, risk factors and outcomes of delayed-onset cytomegalovirus disease in a large retrospective cohort of lung transplant recipients","volume":"99","author":"Santos","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.jiac.2026.102986_bib2","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/TP.0000000000005374","article-title":"The fourth international consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"109","author":"Kotton","year":"2025","journal-title":"Transplantation"},{"key":"10.1016\/j.jiac.2026.102986_bib3","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/tid.12456","article-title":"Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration","volume":"17","author":"Takahata","year":"2015","journal-title":"Transpl Infect Dis"},{"issue":"11","key":"10.1016\/j.jiac.2026.102986_bib4","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.3390\/microorganisms12112360","article-title":"CMV infection risk factors and viral dynamics after valganciclovir prophylaxis: 10 years of experience in lung transplant recipients","volume":"12","author":"Garc\u00eda-Masedo Fern\u00e1ndez","year":"2024","journal-title":"Microorganisms"},{"issue":"5","key":"10.1016\/j.jiac.2026.102986_bib5","first-page":"377","article-title":"Cytomegalovirus infection in lung transplant recipients","volume":"11","author":"Almaghrabi","year":"2017","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jiac.2026.102986_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12887-017-0933-6","article-title":"Emerging (val)ganciclovir resistance during treatment of congenital CMV infection: a case report and review of the literature","volume":"17","author":"Morillo-Gutierrez","year":"2017","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.jiac.2026.102986_bib7","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/tid.12317","article-title":"Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients","volume":"16","author":"Gagermeier","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jiac.2026.102986_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/antibiotics10010077","article-title":"Valganciclovir-ganciclovir use and systematic therapeutic drug monitoring. An invitation to antiviral stewardship","volume":"10","author":"Galar","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jiac.2026.102986_bib9","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/jac\/dkab195","article-title":"Ganciclovir therapeutic drug monitoring in transplant recipients","volume":"76","author":"M\u00e4rtson","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2026.102986_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.healun.2011.11.016","article-title":"Evaluation of valganciclovir pharmacokinetics in lung transplant recipients","volume":"31","author":"Kiser","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jiac.2026.102986_bib11","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1128\/AAC.00836-08","article-title":"Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir","volume":"53","author":"Perrottet","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2026.102986_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14141","article-title":"Trough ganciclovir concentration as predictor of leukopenia in lung transplant recipients receiving valganciclovir prophylaxis","volume":"25","author":"Katada","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jiac.2026.102986_bib13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40780-024-00352-y","article-title":"A case of successful contribution of therapeutic drug monitoring of valganciclovir as the prophylaxis against cytomegalovirus infection in a lung transplant recipient","volume":"10","author":"Katada","year":"2024","journal-title":"J Pharm Health Care Sci"},{"issue":"5","key":"10.1016\/j.jiac.2026.102986_bib14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.jiac.2026.102986_bib15","first-page":"1","article-title":"Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group, KDIGO clinical practice guideline for acute kidney injury","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.jiac.2026.102986_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0166-3542(94)90048-5","article-title":"Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication","volume":"24","author":"Nokta","year":"1994","journal-title":"Antivir Res"},{"key":"10.1016\/j.jiac.2026.102986_bib17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00007890-200002150-00014","article-title":"Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients","volume":"69","author":"Fishman","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.jiac.2026.102986_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14000","article-title":"Burden of neutropenia and leukopenia among adult kidney transplant recipients: a systematic literature review of observational studies","volume":"25","author":"Raval","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jiac.2026.102986_bib19","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jac\/dkv342","article-title":"Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?","volume":"71","author":"Billat","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2026.102986_bib20","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1016\/j.ekir.2024.07.010","article-title":"Pilot study of valganciclovir-induced leukopenia in kidney transplant recipients with NUDT15 genetic variation","volume":"9","author":"Bahadur","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jiac.2026.102986_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/tid.70108","article-title":"NUDT15 genetic polymorphism as a risk factor for early neutropenia during valganciclovir prophylaxis in lung transplant patients","author":"Katsube","year":"2025","journal-title":"Transpl Infect Dis"},{"issue":"10","key":"10.1016\/j.jiac.2026.102986_bib22","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.ajt.2023.06.014","article-title":"Lung transplant recipients with telomere-mediated pulmonary fibrosis have increased risk for hematologic complications","volume":"23","author":"Hannan","year":"2023","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.jiac.2026.102986_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01855-18","article-title":"Relationship of ganciclovir therapeutic drug monitoring with clinical efficacy and patient safety","volume":"63","author":"Ritchie","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.jiac.2026.102986_bib24","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s40262-025-01526-z","article-title":"Pharmacokinetic\/pharmacodynamic modelling and monte carlo simulations to predict cytomegalovirus viral load in pediatric transplant recipients treated with (val)ganciclovir","volume":"64","author":"Koloskoff","year":"2025","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.jiac.2026.102986_bib25","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/FTD.0000000000001054","article-title":"Therapeutic drug monitoring of ganciclovir in cytomegalovirus-infected patients with solid organ transplants and its correlation to efficacy and toxicity","volume":"45","author":"van der Wekken-Pas","year":"2023","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.jiac.2026.102986_bib26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10238-024-01330-2","article-title":"Letermovir prophylaxis for cytomegalovirus in lung-transplant recipients: a comprehensive study with literature review of off-label use and real-world experiences","volume":"24","author":"Hirama","year":"2024","journal-title":"Clin Exp Med"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2600084X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2600084X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:27:11Z","timestamp":1783146431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X2600084X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1341321X2600084X"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2026.102986","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valganciclovir therapeutic drug monitoring-guided dosing for cytomegalovirus prophylaxis in lung transplant patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2026.102986","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102986"}}